Nolato AB (publ) (STO:NOLA.B)
62.20
-0.15 (-0.24%)
Oct 30, 2025, 9:29 AM CET
Nolato AB Revenue
Nolato AB had revenue of 2.34B SEK in the quarter ending September 30, 2025, a decrease of -2.46%. This brings the company's revenue in the last twelve months to 9.57B, up 0.40% year-over-year. In the year 2024, Nolato AB had annual revenue of 9.66B with 1.24% growth.
Revenue (ttm)
9.57B
Revenue Growth
+0.40%
P/S Ratio
1.75
Revenue / Employee
1.73M
Employees
5,837
Market Cap
16.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.66B | 118.00M | 1.24% |
| Dec 31, 2023 | 9.55B | -1.23B | -11.40% |
| Dec 31, 2022 | 10.77B | -836.00M | -7.20% |
| Dec 31, 2021 | 11.61B | 2.25B | 24.05% |
| Dec 31, 2020 | 9.36B | 1.44B | 18.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.53B |
| Vimian Group AB | 4.65B |
| Vitrolife AB | 3.51B |
Nolato AB News
- 1 day ago - Nolato AB (publ) (NLTBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Q2 2025 Nolato AB Earnings Call Transcript - GuruFocus
- 9 months ago - Nolato AB (STU:NBF) Q4 2024 Earnings Call Highlights: Strong Profit Growth Amid Sector Challenges - GuruFocus
- 9 months ago - Q4 2024 Nolato AB Earnings Call Transcript - GuruFocus
- 2 years ago - Cyclical Industrials' Turnaround Is Close, Though Nolato Isn't Cheap, It's Still A Buy - Seeking Alpha